Improving Home Dialysis Act of 2026

On May 19, 2026, Rep. Carol Miller (R-WV) introduced H.R. 8875, the Improving Home Dialysis Act of 2026, which amends the Social Security Act to include staff-assisted home dialysis respite care and renal mental health services as Medicare-covered self-care home dialysis support services, effective January 1, 2028. The bill has been referred to the Committees on Energy and Commerce and Ways and Means — both have jurisdiction over Medicare reimbursement policy. As an early-stage bill, it faces a long legislative path: committee hearings, markups, floor votes in both chambers, and potential reconciliation with a Senate companion bill (none yet). The bill does not authorize or appropriate any specific dollar amount; it expands the scope of covered services under existing Medicare Part B reimbursement for dialysis. The money trail flows through Medicare Administrative Contractors to dialysis providers who deliver these new services. The primary beneficiaries are dialysis providers with significant home dialysis programs: DaVita and Fresenius Medical Care ($FMS). Both companies have been actively converting patients from in-center hemodialysis to home modalities (peritoneal dialysis and home hemodialysis) to reduce costs and improve patient outcomes. This bill removes a key barrier — lack of support services — by reimbursing for temporary staff assistance when a home patient is unable to self-dialyze (e.g., due to illness or physical limitation) and for renal mental health services. This makes home dialysis more accessible and reduces the risk of hospitalization or transfer back to in-center care. The financial impact is moderate: home dialysis currently accounts for ~12-15% of U.S. dialysis patients, but per-patient margins are higher (home PD margins ~30-40% vs. in-center ~15-20%). Adding these new service codes could increase per-patient home dialysis revenue by 5-10%, translating to an estimated $50-100 million annual revenue uplift for each of the two largest providers. Novo Nordisk ($NVO) has a tangential interest through its kidney disease pipeline, but the direct revenue impact is minimal. No real market data on stock price movements is available for this specific event, but the structural trend toward home dialysis is well-established and this bill accelerates it. The timeline: earliest possible enactment is late 2026 or 2027, with services starting January 1, 2028. Investors should monitor committee activity and any Senate companion bill introduction as key catalysts.